You are here


Since 2015, BiomX has been discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and skin disorders that stem from microbiome dysbiosis. The Company’s microbiome modulation platform uses cutting-edge science, research, and licensed technology created by Professor Rotem Sorek, Ph.D., and Dr. Eran Elinav, M.D./Ph.D., both of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D./Ph.D., of The Massachusetts Institute of Technology.
Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset Global Investments, and SBI. Microbiome is a new and fast-developing field at the junction of nutrition and pharmaceuticals. BiomX offer a complete solution ranging from target discovery to therapeutic compounds. We have unique capabilities to modulate the microbiome and address dysbiosis through adding or eradicating bacteria with both native phages and synthetic phage that we engineer